At Sentrimed, we are discovering and developing novel therapies that harness critical cell-to-cell communication processes essential to reviving the body’s ability to recognize, contain and eliminate abnormal cells found in cancer and potentially malignant conditions. We are leaders in contact normalization, a cellular communication process that enables normal cells to not only inhibit tumor growth and spread, but also enables subsequent tumor elimination. Our therapies target specific receptors that potentially precancerous and tumor cells use to escape contact normalization. This approach disables key pathways critical to disease progression.
We are developing a robust pipeline based on the seminal research of our scientific team. Our scientific founder, Dr. Gary Goldberg, is internationally recognized for his research on cell-to-cell communication. Together, with our scientific board members, Dr. Goldberg has made significant discoveries about the pivotal role of contact normalization in the body’s ability to evade cancer.
Our lead product, MASL, is a novel, orally dosed therapeutic that has been validated in preclinical studies conducted by leading research institutes, including the NCI. MASL is a powerful inhibitor of podoplanin (PDPN) signaling. PDPN is a transmembrane receptor glycoprotein that is overexpressed in many cancers and is critical in tumor progression. It is also an early expressed tumor biomarker correlated with poor prognosis in many cancers. By binding to PDPN, MASL inhibits tumor cell growth and invasion, and triggers cancer cell destruction. MASL is currently being evaluated in a Phase 1 clinical trial in oral cancer and could change the cancer treatment paradigm from “watch and wait” to “treat and prevent.”